Indomethacin
| Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
|---|---|---|---|
| NSAIDs | Indomethacin | AVOID if possible; 25mg PO Q12H | Administer Anytime During HD |
|
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 358 | 30 | 4-12 | Unchanged | 99 | 0.12 | 19.9 | 19.6 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00328
- Skoutakis V, Acchiardo S, Carter C, et al. Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. Drug intelligence & clinical pharmacy. 1986;20(12):956-60.